ESMO 2026 First Glance at Relevant Titles for Us: ONC INCY IMTX in Focus

Research evidence excerpt

ESMO 2026 First Glance at Relevant Titles for Us: ONC INCY IMTX in Focus

e and with HMA ±

10/24/2026 BNTX / BMY SMMT pumitamig PD-1/VEGF 1951RO Efficacywith brainof metastases:pumitamig (PD-L1a subgroup× VEGF-AanalysisbsAb)ofplustwo chemotherapyphase 2 trials in patients with SCLC or TNBC

10/24/2026 Cstone Pharma SMMT CS2009 PD-1/VEGF/CTLA-4 1953RO Safetymetastaticand efficacycolorectalof cancerCS2009,(mCRC):a first-in-classResults PD-1/VEGF/CTLA-4from a phase 1/2 studytrispecific antibody, in

10/24/2026 BNTX / Duality SMMT pumitamigElfe-D + PD-1/VEGFB7-H3 x 999O ElfetabartbsAb) in patientsdrozuntecanwith advanced(Elfe-D; DB-1311/BNT324solid tumors: First[B7H3resultsADC])from+ apumitamigglobal phase(PD-L12 trialx VEGF-A

10/25/2026 Cstone Pharma SMMT CS2009 PD-1/VEGF/CTLA-4 2616RO Awithphaseadvanced2 studynon-smallof CS2009,cella first-in-classlung cancer (NSCLC)PD-1/VEGF/CTLA-4 trispecific antibody, in patients

Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Monotherapy or in

10/25/2026 INCY INCB161734 G12D 1007RO Combination with Cetuximab (Cetux) in Patients (pts) with Advanced/Metastatic Colorectal

Cancer (CRC)

Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with

10/25/2026 INCY INCB161734 G12D 3137RO Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal

Adenocarcinoma (PDAC)

10/25/2026 MedicinesFrontier RVMD FMC-376 G12C 1006RO PhaseKRAS G12C1 studymutantof FMC-376,solid tumors.a KRAS G12C equipotent ON+OFF inhibitor in pts with advanced

Efficacy and Safety of AK112 (Ivonescimab), a PD-1/VEGF Bispecific Antibody, as First-Line

10/25/2026 Akeso SMMT Ivonescimab PD-1/VEGF 3592RO Treatment for Patients with IMDC Favorable-Risk Advanced Renal Cell Carcinoma (aRCC):

Results from a Phase Ib/II Study